🇺🇸 FDA
Pipeline program

Zasocitinib

TAK-279-PsA-3002

Phase 3 small_molecule active

Quick answer

Zasocitinib for Psoriatic Arthritis is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 3 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Psoriatic Arthritis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials